I'll post both Pfizer, and Merck detailed listings later this week -- but here's where the vast bulk of Amgen shareholders' lobby-spend money went:
. . .Issues related to drug pricing reform; H.R.5376, Build Back Better Act; S2891 Restoring America Invents Act; S1435 affordable prescriptions for patients act; H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act; H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; Biosimilars reimbursement issues, no specific bill; Supply Chain Issues, no specific bill; Issues related to clinical trial diversity, HR 6584 DEPICT Act, HR5030 DIVERSE Trials Act, HR 7845 and S2706 NIH Clinical Trial Diversity Act of 2022; Issues related to biodefense issues, S3799 PREVENT Pandemics Act; Issues related to cardiovascular disease awareness, S. 3018/ HR 3173 Improving Seniors Timely Access to Care Act. . . .
S.464 Safe Step Act and HR8295 Labor/HHS Appropriations bill; H.R. 5801 HELP Copays Act; Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters; FDA Issues; User Fee Reauthorization HR7667 Food and Drug Amendments Act and S4348 FDA safety and landmark advancement act; H.R. 6963, the Accelerated Approval Integrity Act of 2022; H.R. 7047, a bill to amend Title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes; H.R. 6000, the Cures 2.0 Act; H.R. 7008, the Pre-Approval Information Exchange Act; S4293 Pharmacy benefit managers transparency act; HR 8588Fair Care Act, 340B hospital reporting; HR 4390 Protect 340B Act. . . .
Issues related to drug pricing reform and Medicare Part D redesign; H.R. 5376 Build Back Better Act; S. 1943 and H.R. 3517, Issues related to DXA scans, osteoporosis; Issues related to cardiovascular disease awareness; Issues related to ESRD bundle; Issues related to asthma and self-administered drug list; S. 2428 False Claims Amendments Act of 2021; Reimbursement for biologics/biosimilars; Issues related to discarded drugs. . . .
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Final Rule, Guidance Related to the Foreign Tax Credit and Clarification of Foreign-Derived Intangible Income; Issues related to OECD negotiations on the taxation of global income; H.R. 5376, Bill to provide for reconciliation pursuant to title I of S. Con. Res. 14. . . .
S.1435 Affordable Prescriptions for Patients Act; H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act; H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; S 2891 Restore the America Invents Act; S. 2774- Pride in Patent Ownership Act; S. 4704- Patent Examination and Quality Improvement Act of 2022; S. 4417- Patent Trial and Appeal Board Reform Act of 2022; S. 4430- Interagency Patent Coordination and Improvement Act of 2022; FTC related issues, no specific bill; Issues related to the Patent Act; Issues related to march-in/Bayh Dole, WTO/TRIPS waiver, no specific bill; Mergers and acquisitions, no specific bill. . . .
As I say, Amazon outspent them all [and. . . this quarter at least, Amazon handily outspent Apple (which only spent $1.9 million though its enterprise value is many multiples of these others, and its businesses are more complicated)]. Amazon almost spent more than the other three listed above, combined -- and it pushed hard on US labor laws, and on global tax measures -- as well as telecom regulations.
Now, sleep tight -- and. . . don't let the bed-bugs bite, you pumpkin-patch buckaroos and buck-a-rettes! Smile. . . .
नमस्ते
No comments:
Post a Comment